BioAge Labs Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Revenue	10.32	9	-	-	-
Revenue Growth	610.96%	-	-	-	-
Gross Profit	10.32	9	-	-	-
Selling, General & Admin	28.76	27.81	19.16	14.51	9.45
Research & Development	83.27	73.97	59.04	33.89	30.52
Total Operating Expenses	112.03	101.78	78.19	48.4	39.97
Operating Income	-101.71	-92.78	-78.19	-48.4	-39.97
Interest Income	12.64	13.09	9.63	2.43	0.47
Interest Expense	-0.48	-0.7	-2.37	-7.79	-0.24
Other Non-Operating Income (Expense)	-0.38	-0.21	-0.18	-10.09	0.02
Total Non-Operating Income (Expense)	11.78	12.18	7.09	-15.45	0.25
Pretax Income	-89.93	-80.61	-71.11	-63.85	-39.72
Net Income	-89.93	-80.61	-71.11	-63.85	-39.72
Net Income to Common	-89.93	-80.61	-71.11	-63.85	-39.72
Net Income Growth	-	-	-	-	-
Shares Outstanding (Basic)	38	36	11	2	2
Shares Outstanding (Diluted)	38	36	11	2	2
Shares Change	95.10%	234.99%	541.23%	0.06%	-
EPS (Basic)	-2.40	-2.24	-6.63	-38.17	23.76
EPS (Diluted)	-2.40	-2.24	-6.63	-38.17	23.76
EPS Growth	-	-	-	-	-
Free Cash Flow	-88.63	-82.35	-51.89	-37.53	-36.28
Free Cash Flow Growth	-	-	-	-	-
Free Cash Flow Per Share	-2.36	-2.29	-4.84	-22.43	-21.70
Gross Margin	100.00%	100.00%	-	-	-
Operating Margin	-985.93%	-1031.46%	-	-	-
Profit Margin	-871.75%	-896.11%	-	-	-
FCF Margin	-859.14%	-915.46%	-	-	-
EBITDA	-101.47	-92.57	-78.03	-48.24	-39.84
EBITDA Margin	-983.62%	-1029.09%	-	-	-
EBIT	-101.71	-92.78	-78.19	-48.4	-39.97
EBIT Margin	-985.93%	-1031.46%	-	-	-

SEC Filings: 10-K · 10-Q